Oral lipid formulation type IV as an approach in the formulation of solid dosage forms with poorly soluble substances: Chremophor®RH 40 as a surfactant phase

Oral lipid formulation type IV as an approach in the formulation of solid dosage forms with poorly soluble substances: Chremophor®RH 40 as a surfactant phase

Authors

  • Tanja Vojinović University of Montenegro, Faculty of Medicine, Krusevac 81 000, Podgorica, Montenegro
  • Jelena Djuris University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Technology
  • Zorica Potpara University of Montenegro, Faculty of Medicine
  • Svetlana Ibric University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Technology

Keywords:

Gliclazide; Cremophor®RH40; Oral solid lipid formulations; Neusilin®UFL2

Abstract

Aim of this study was investigation into solid oral lipid formulations with poorly soluble substance gliclazide, using non-ionic surfactant Cremophor®RH40. The use of a new approach to the formulation of type IV of solid oral lipid formulations is described. Drug/surfactant solution was adsorbed on magnesium-aluminium metasilicate (Neusilin®UFL2) carrier with or without addition of superdisintegrant and filled into hard gelatin capsules or compressed into tablets. In this way, a very fast and complete dissolution of poorly soluble drug is achieved. This study shown that with proper selection of ratio of drug/surfactant/adsorbent, with or without superdisintegrant in formulation, it is possible to achieve rapid dissolving of poorly soluble drug from solid dosage forms.

References

Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif Cells Nanomed Biotechnol 2016;44(6):1508-19.

Colin W, Pouton C.W, Christopher J.H. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliver Rev 2008; 60:625–637.

Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29: 278–287.

Strickley R.G, in: D.J. Hauss (Ed.). Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs. Informa Healthcare New York 2007; pp. 1–31.

Ewart T.C, Dominique C, Hassan B. Challenges and Opportunities in The Encapsulation of Liquid and Semi-Solid Formulations into Capsules for Oral Administration. Adv Drug Deliver Rev 2008; 60:747-756.

Bowtle W.J, in: D.J. Hauss (Ed.). Oral Lipid-Based Formulations - Enhancing the Bioavailability of Poorly Water-Soluble Drugs. Informa Healthcare New York 2007; pp. 79–106.

Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliver Rev 2008; 60:734 – 746.

Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mat 2009; 117: 1–9.

Downloads

Published

07-10-2021

Issue

Section

Original articles

How to Cite

1.
Vojinović T, Djuris J, Potpara Z, Ibric S. Oral lipid formulation type IV as an approach in the formulation of solid dosage forms with poorly soluble substances: Chremophor®RH 40 as a surfactant phase. Progr Nutr [Internet]. 2021 Oct. 7 [cited 2025 May 1];23(3):e2021279. Available from: https://mattioli1885journals.com/index.php/progressinnutrition/article/view/12071